

# UK NEQAS

Leucocyte Immunophenotyping

2025 - 2026

## Full Programme List

EQA/PT Programmes for Flow Cytometry  
and Molecular Haemato-Oncology

**EQA** International

Working in partnership with UK NEQAS LI



[www.ukneqasli.co.uk](http://www.ukneqasli.co.uk)

## 2025 - 2026 Full Programme List - EQA/PT Programmes for Flow Cytometry and Molecular Haemato-Oncology

### Flow Cytometry Programmes

- CD34+ Stem Cell Enumeration
- Cerebrospinal Fluid (CSF) Immunophenotyping\*
- Competency Assessment and Instrument Validation Panel for Immune Monitoring
- Haematological Malignancy Bone Marrow Aspirate Assessment\*
- Immune Monitoring
- Leukaemia Immunophenotyping and Diagnostic Interpretation
- Leukaemia Diagnostic Interpretation - Institute Registration
- Leukaemia Diagnostic Interpretation - Individual Registration
- Low Level Leucocyte Enumeration
- Measurable Residual Disease for ALL by Flow Cytometry
- Measurable Residual Disease for AML by Flow Cytometry\*
- Measurable Residual Disease for CLL by Flow Cytometry\*
- Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry\*
- Paroxysmal Nocturnal Haemoglobinuria

### Molecular Haemato-Oncology Programmes

- *BCR::ABL1* and AML Translocation Identification
- *BCR::ABL1* Kinase Domain Variant (Mutation) Status
- *BCR::ABL1* Major Quantification
- *BCR::ABL1* Minor Quantification
- *BRAF* p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia
- *FLT3* Mutation Status
- IG/TCR Clonality Status
- *KIT* p.Asp816Val (D816V) Mutation Status for Mast Cell Disease
- Lymphoid Gene Panels\*
- Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia
- Measurable Residual Disease for AML by Molecular Methods\*
- Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods\*
- Myeloid Gene Panels\*
- Myeloproliferative Neoplasms Diagnostic Testing\*\*
- *NPM1* Mutation Status
- Paediatric Acute Leukaemia Translocations
- Post-Stem Cell Transplant Chimerism Monitoring

\* Please note that the *JAK2* p.Val617Phe Mutation Status programme is now incorporated within the Myeloproliferative Neoplasms Diagnostic testing programme. Accreditation of the remaining markers is anticipated by the end of 2025.

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI  
Pegasus House  
4<sup>th</sup> Floor Suite  
463a Glossop Road  
Sheffield S10 2QD  
United Kingdom

Tel: +44 (0)114 2673600  
Fax: +44 (0)114 2673601

email: [admin@ukneqasli.co.uk](mailto:admin@ukneqasli.co.uk)  
[www.ukneqasli.co.uk](http://www.ukneqasli.co.uk)

Please note that if your participation with UK NEQAS LI is via a non-UK distributor you should contact them directly for details of how to register. If you are enquiring from outside of the UK your registration will be managed by EQA International Ltd.